What it's actually good for
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell needs for energy metabolism and DNA repair, and it declines measurably with age — that part isn't controversial. What's controversial is what happens when you push it back up with a precursor supplement. In mice, restoring NAD+ with NMN or NR reliably improves mitochondrial function and multiple biomarkers researchers use as proxies for "healthspan" (Canto et al., 2015). In humans, the picture is narrower: oral NMN and NR both raise blood NAD+ reliably and dose-dependently. Raising a biomarker isn't the same as producing a clinical benefit, and that gap is exactly where the evidence for NAD+ precursors currently stalls — which is why this file is graded C despite the genuine mechanistic interest.
What the research says
NAD+ goes up — this part is settled. Martens et al. (2018, Nature Communications) showed chronic NR supplementation is well-tolerated and reliably elevates NAD+ in healthy middle-aged and older adults. This is the most reproducible finding in the field.
Functional outcomes — one promising trial, not a pattern yet. A 2023 Geroscience RCT (Yi et al.) gave 80 healthy middle-aged adults 300-900 mg/day of NMN for 60 days and found improved six-minute walk distance and quality-of-life scores versus placebo, with a slower rise in a composite "biological age" score. That's a real, controlled result — but it's a single trial using surrogate and composite endpoints, not hard outcomes like disease incidence or mortality, and it hasn't been independently replicated.
Metabolic markers — no signal so far. Zoom in on the metabolic claims specifically and the evidence gets weaker: a 2024 systematic review and meta-analysis (Chen et al., Current Diabetes Reports) pooling 8 RCTs and 342 participants found no significant effect of NMN on fasting glucose, insulin, HbA1c, or lipids. Put the three findings together and the honest summary is: NAD+ rises reliably, one short trial found improved physical function and quality of life, and metabolic markers haven't moved. Nobody has run a trial long enough to test whether any of this changes disease risk or lifespan in people — which is the claim the marketing usually implies.
How much, and which form
Trial doses have ranged 250-1,000 mg/day for NMN and 300-1,000 mg/day for NR, taken as capsules, sublingual tablets, or powder. NR has one dominant, well-characterized commercial form (Niagen), which also carries the most published human safety data of any precursor. NMN's U.S. regulatory status has been unstable — the FDA moved in 2022 to exclude it from the dietary supplement definition over its prior investigation as a drug, which has periodically disrupted retail availability — so label accuracy and sourcing deserve extra scrutiny if you're buying NMN specifically rather than NR.
Safety & interactions
Short-term trials (up to 12 weeks) report no meaningful increase in adverse events for either NR or NMN at typical doses, with occasional mild GI upset. What's missing is long-term human data — nobody has studied years of continuous use. The theoretical concern worth naming plainly: because NAD+ supports cell proliferation broadly, boosting it could in principle feed an existing, undiagnosed tumor. This hasn't been demonstrated in human trials, but it also hasn't been ruled out, since no trial has run long enough or in a high-risk population to check. This is informational, not medical advice — talk to a clinician before starting, especially with a personal or family cancer history.
How we picked the brand
A NAD+ precursor earns a spot when it uses a well-characterized, third-party-verified form — Niagen for NR is the clearest case — states the exact compound and dose per serving, and skips proprietary blends. Given how unsettled the human evidence still is, this is a category to buy cautiously, not aggressively.